Article

Andrew Dunn for Business Insider
Jun 29 ’20

The biotech giant Gilead just laid out its pricing strategy for the first effective coronavirus treatment, and it’s charging up to $520 a vial for remdesivir

auteur

Get notified of new articles from this auteur